This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock RTRX vs. MENS, GMTX, MOR, ZYME, CALT, ETHZ, SBTX, AVTE, NLTX, and BIOAShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Jyong Biotech (MENS), Gemini Therapeutics (GMTX), MorphoSys (MOR), Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Flag Ship Acquisition (ETHZ), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), and BioAge Labs (BIOA). Travere Therapeutics vs. Its Competitors Jyong Biotech Gemini Therapeutics MorphoSys Zymeworks Calliditas Therapeutics AB (publ) Flag Ship Acquisition Silverback Therapeutics Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Travere Therapeutics (NASDAQ:RTRX) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical preparations industry companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Which has preferable valuation and earnings, RTRX or MENS? Jyong Biotech has lower revenue, but higher earnings than Travere Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$175.34M7.95-$146.43M-$3.46-7.90Jyong BiotechN/AN/AN/AN/AN/A Is RTRX or MENS more profitable? Jyong Biotech has a net margin of 0.00% compared to Travere Therapeutics' net margin of -49.13%. Jyong Biotech's return on equity of 0.00% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-49.13% -36.38% -14.90% Jyong Biotech N/A N/A N/A Do analysts prefer RTRX or MENS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media favor RTRX or MENS? In the previous week, Jyong Biotech had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 1 mentions for Jyong Biotech and 0 mentions for Travere Therapeutics. Jyong Biotech's average media sentiment score of 0.88 beat Travere Therapeutics' score of 0.00 indicating that Jyong Biotech is being referred to more favorably in the news media. Company Overall Sentiment Travere Therapeutics Neutral Jyong Biotech Positive SummaryJyong Biotech beats Travere Therapeutics on 6 of the 7 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.39B$1.03B$6.09B$10.49BDividend YieldN/A4.84%5.73%4.80%P/E Ratio-12.951.3285.3027.13Price / Sales7.95147.79519.71179.96Price / CashN/A17.6337.2361.22Price / Book5.308.0712.236.52Net Income-$146.43M-$7.36M$3.33B$276.93M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$27.32-0.7%N/A+52.4%$1.39B$175.34M-12.95221High Trading VolumeMENSJyong BiotechN/A$51.14-7.2%N/AN/A$3.89BN/A0.0031High Trading VolumeGMTXGemini TherapeuticsN/A$67.89-2.0%N/A+54.9%$2.94BN/A-67.8930Gap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ZYMEZymeworks0.2671 of 5 stars$16.68+1.1%N/AN/A$1.25B$76.30M-17.20460News CoverageAnalyst UpgradeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ETHZFlag Ship AcquisitionN/A$2.32-0.4%N/AN/A$381.48MN/A-0.157News CoverageStock SplitGap DownSBTXSilverback TherapeuticsN/A$10.33+0.6%N/A-38.8%$372.48MN/A-4.2783High Trading VolumeAVTEAerovate TherapeuticsN/A$9.04-1.1%N/A-87.9%$262.02MN/A-3.0220High Trading VolumeNLTXNeoleukin TherapeuticsN/A$23.47+1.6%N/A-35.8%$220.57MN/A-7.5590News CoverageHigh Trading VolumeBIOABioAge LabsN/A$5.67+1.3%N/AN/A$203.27MN/A0.00N/A Related Companies and Tools Related Companies Jyong Biotech Alternatives Gemini Therapeutics Alternatives MorphoSys Alternatives Zymeworks Alternatives Calliditas Therapeutics AB (publ) Alternatives Flag Ship Acquisition Alternatives Silverback Therapeutics Alternatives Aerovate Therapeutics Alternatives Neoleukin Therapeutics Alternatives BioAge Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTRX) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
